Sanofi executives will provide an overview of the growth and development strategy for Dupixent (dupilumab) in the third of its five-part series to highlight Sanofi’s progress. Sanofi co-develops and co-commercializes Dupixent with Regeneron (REGN).
The company is targeting the below additional indications.
- Eosinophilic Esophagitis (EoE)
- Chronic Obstructive Pulmonary Disease (COPD) with Evidence of Type 2 Inflammation
- Prurigo Nodularis (PN)
- Chronic Spontaneous Urticaria (CSU)
- Bullous Pemphigoid (BP)
All of these potential uses are investigational, and the safety and efficacy of Dupixent in any of these indications has not been evaluated yet.
While additional data contribute to the growing body of evidence demonstrating Dupixent’s best in class safety profile combined with strong efficacy benefit for atopic dermatitis and further validate it as a standard of care treatment for asthma; Dupixent’s unique mechanism of action simultaneously inhibits IL-4 and IL-13, which play a key role in type 2 inflammation in multiple diseases.